- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07583342
Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
Open-label, Multicenter, Phase IV, Study Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is:
Does Relizorb allow more nutrition to be delivered to participants than they received without it?
Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Bay Shore, New York, États-Unis, 11706
- South Shore University Hospital
-
Manhasset, New York, États-Unis, 11030
- North Shore University Hospital
-
Manhattan, New York, États-Unis, 10075
- Lenox Hill Hospital
-
New Hyde Park, New York, États-Unis, 11040
- Long Island Jewish Medical Center
-
Staten Island, New York, États-Unis, 10305
- Staten Island University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Male or female aged 18 + years of age
- Admission to the Surgical Intensive Care Unit in the Northwell Health hospital system
- Moderate to severe acute pancreatitis based on Atlanta criteria
- Inability to tolerate ≥75% of goal EN (25 kcal/kg/d)
Exclusion Criteria:
- Moribund patients expected to expire within 120 hours
- Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuity, or other contraindication for enteral nutrition
- Diagnosis or evidence of C. Difficile or other gastrointestinal infection that may manifest with diarrhea
- Pre-existing constipation defined as laxative or stool softener use prior to admission to the hospital
- Patients receiving cancer-related treatment in the last 3 months
- History of cystic fibrosis
- Any other reason that the treating or investigator team considers to be a contraindication to enteral nutrition
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Relizorb treatment
Patients with moderate to severe pancreatitis who are not tolerating sufficient enteral nutrition will have a lipase-containing cartridge (Relizorb) placed in-line with their enteral nutrition tubing, to digest the fat in the formula prior to entering the patient's intestine.
|
An in-line digestive enzyme cartridge designed for hydrolyzing lipids within enteral nutrition will be used to improve tube feed tolerance in patients with moderate to severe pancreatitis.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent of goal nutrition delivered at 72 hours
Délai: From enrollment to the end of treatment at 72 hours
|
Change from baseline in percentage of goal enteral nutrition (kcal/kg/day) received 3 days (72 hours) following initiation of RELiZORB.
Baseline is considered the 24 hours prior to RELiZORB start.
|
From enrollment to the end of treatment at 72 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent of goal nutrition delivered at 24 hours
Délai: From enrollment to 24 hours after starting RELiZORB
|
Change from baseline in goal percentage of enteral nutrition (kcal/kg/day) received 1 day (24 hours) following initiation of RELiZORB.
|
From enrollment to 24 hours after starting RELiZORB
|
|
Responders at 72 hours
Délai: From enrollment to end of treatment at 72 hours
|
Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 3 days (72 hours) following initiation of RELiZORB use.
|
From enrollment to end of treatment at 72 hours
|
|
Responders at 24 hours
Délai: From enrollment to 24 hours after starting treatment
|
Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 1 day (24 hours) following initiation of RELiZORB use.
|
From enrollment to 24 hours after starting treatment
|
|
Vomiting
Délai: From enrollment to completion of treatment at 72 hours
|
Change in the number of vomiting episodes per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use
|
From enrollment to completion of treatment at 72 hours
|
|
Stool volume
Délai: From enrollment to completion of treatment at 72 hours
|
Change in stool volume per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use (if rectal tube is in place)
|
From enrollment to completion of treatment at 72 hours
|
|
Bowel movements
Délai: From enrollment to completion of treatment at 72 hours
|
Change in number of bowel movement episodes in 24 hours from baseline to 24 hours and 72 hours after RELiZORB (if no rectal tube)
|
From enrollment to completion of treatment at 72 hours
|
|
Feeding Interruptions
Délai: From enrollment to completion of treatment at 72 hours
|
Number of unplanned interruptions in tube feeding from baseline to 24 hours and 72 hours following initiation of RELiZORB use
|
From enrollment to completion of treatment at 72 hours
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Laura Hansen, MD, Northwell Health
- Chercheur principal: Rafael Barrera, MD, Northwell Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 25-0106-LIJ
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .